Stocktoria
Ernexa Therapeutics Inc. ERNA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 1991-08-29
Ernexa Therapeutics Inc. statistics & valuation
Market cap$8.1M
P / B3.4×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | — | 83.5% | -247.1% | — | — |
| Operating margin | — | -2693.1% | -31080.9% | — | — |
| Net margin | — | -7652.7% | -31864.7% | — | — |
| FCF margin | — | -2784.4% | -30039.7% | — | — |
| Return on assets | -241.4% | -845.3% | -44.1% | -110.3% | -388.7% |
| Return on equity | -586.6% | -2618.4% | -970.4% | -203.0% | -480.5% |
| Current ratio | 1.01 | 0.80 | 1.46 | 1.79 | 5.10 |
| Revenue growth | — | 755.9% | — | — | — |
Source: SEC EDGAR filings · CIK 0000748592 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.